Application of pyruvic acid compound in improving sperm motility

Abstract

The invention relates to the technical field of medicines, in particular to application of a pyruvic acid compound in improving sperm motility, which is characterized in that the pyruvic acid compound is selected from pyruvic acid, pyruvate or a mixture thereof; the pyruvate is one or more of lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate or manganese pyruvate, the proportion (PR) of forward moving sperms of an experimental group (E1-E10) is increased by 67.3% (E10 group) to the maximum compared with that of a control group, the curve speed (VCL) is increased by 51.8% (E5 group), the survival rate is increased by 38.3% (E10 group), and the experimental group (E1-E10) has the advantages that the experimental group (E1-E10) has the advantages that the experimental group (E1-E10) has the advantages that the experimental group (E1-E10) has the advantages that the experimental group (E1-E10) can be used for preparing the sperm- The pyruvic acid compound solves the core problem of low sperm motility from the mechanism by simultaneously regulating energy metabolism (providing ATP) and reducing oxidative stress (clearing ROS), and avoids the limitation of single therapy, the selected pyruvate (such as sodium, potassium and magnesium salts) has no cytotoxicity, and the auxiliary materials (such as glycerol and hydroxyethyl cellulose) in the dosage form are medicinal and high in safety.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of medicine, in particular to the application of pyruvic acid compounds in enhancing sperm motility. BACKGROUND

[0002] Sperm motility is one of the key factors determining male fertility, directly affecting the sperm's ability to move in the female reproductive tract, penetrate, and successfully combine with the ovum. However, in modern society, due to environmental pollution, unhealthy lifestyle, oxidative stress, and other factors, the quality of male sperm has generally declined, and oligospermia has become one of the common causes of infertility. Therefore, developing effective and safe strategies to enhance sperm motility is of great significance for improving male fertility, increasing the natural pregnancy rate, and optimizing the success rate of assisted reproductive technology (ART).

[0003] Relationship between sperm motility and male infertility

[0004] In male infertility, about 30% to 40% of cases are related to low sperm motility (oligospermia). Sperm motility is a key indicator of male fertility, directly affecting the ability of sperm to penetrate cervical mucus, reach the fallopian tube, and combine with the ovum. The World Health Organization (WHO) standard (6th edition) stipulates that the proportion of progressively motile sperm (PR) in a normal semen sample should be ≥32%, and if it is lower than this threshold, the probability of natural conception is significantly reduced.

[0005] Existing methods for improving sperm motility and their limitations

[0006] Current clinical treatments for oligospermia include:

[0007] Antioxidant therapy (such as vitamin E, coenzyme Q10, and L-carnitine): by reducing oxidative stress damage to improve sperm motility, but the effect varies greatly among individuals, and some patients do not respond well.

[0008] Hormone therapy (such as gonadotropin): suitable for patients with endocrine abnormalities, but may cause side effects (such as testicular function suppression).

[0009] Surgical correction (such as varicocele ligation): only effective for specific causes, with a long recovery period after surgery.

[0010] In vitro sperm optimization techniques (such as density gradient centrifugation and the Upstream method): commonly used in assisted reproduction, but may cause mechanical damage to sperm or accumulation of reactive oxygen species (ROS).

[0011] Significance of improving sperm motility

[0012] Although improving sperm motility is of great value for improving male fertility, optimizing assisted reproductive technology and promoting reproductive medicine research, it is expected to develop safer and more efficient intervention strategies by exploring new mechanisms such as energy metabolism regulation and antioxidant protection, and to provide more choices for clinical treatment. SUMMARY

[0013] The application provides the application of pyruvic acid compounds in improving sperm motility, and by preparing pyruvic acid compounds of a specific formula into a solution, a gel or an emulsion, the motility and survival rate of sperm can be significantly improved.

[0014] To achieve the above object, the application is implemented by the following technical solutions:

[0015] The application provides the application of pyruvic acid compounds in improving sperm motility, and the pyruvic acid compound is selected from pyruvic acid, a pyruvic acid salt or a mixture thereof, the pyruvic acid salt is one or more of lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate or manganese pyruvate.

[0016] Further, the application is realized by preparing pyruvic acid compounds into a drug or a health product, and the drug or the health product is a solution, which comprises the following components in mass percentage:

[0017] Pyruvic acid compound: 0.1% to 1.5%;

[0018] Osmotic pressure regulator: 0.5% to 2%;

[0019] pH regulator: 0.1% to 2.5%;

[0020] Preservative: 0.01% to 0.5%;

[0021] The balance is water.

[0022] Further, the drug or the health product is a gel, which comprises the following components in mass percentage:

[0023] Pyruvic acid compound: 0.1% to 1.5%;

[0024] Colloid base: 0.2% to 1%;

[0025] Osmotic pressure regulator: 0.5% to 2%;

[0026] pH regulator: 0.1% to 2.5%;

[0027] Preservative: 0.01% to 0.5%;

[0028] The balance is water.

[0029] Further, the drug or health product is an emulsion, comprising the following components in mass percentage:

[0030] Pyruvic acid compound: 0.1%~1.5%;

[0031] Oil phase: 15%~35%;

[0032] Osmotic pressure regulator: 0.5%~2%;

[0033] pH regulator: 0.1%~2.5%;

[0034] Preservative: 0.01%~0.5%;

[0035] Emulsifier: 0.1%~0.5%;

[0036] The balance is water.

[0037] Further, the osmotic pressure regulator is selected from one or more of glycerol, glucose, sodium chloride, mannitol, sorbitol, polyethylene glycol or propylene glycol; the pH regulator is selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate or potassium dihydrogen phosphate; the preservative is selected from one or more of polyhexamethylene biguanide, hydroxybenzoic acid ester, hydroxybenzoic acid propyl ester, phenoxy ethanol or octanol.

[0038] Further, the colloidal matrix is selected from one or more of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, sodium alginate or gellan gum.

[0039] Further, the oil phase is selected from one or more of jojoba oil, grape seed oil, sweet almond oil, olive oil, sunflower seed oil, coconut oil, dimethyl silicone oil, isopropyl myristate, ethylhexyl palmitate, caprylic / capric acid triglyceride, white mineral oil or vaseline; the emulsifier is selected from one or more of Tween 20, Tween 80, polyethylene glycol stearate, ceteareth, sodium lauryl sulfate, lecithin, cetearyl alcohol, sucrose ester or glycerol stearate.

[0040] A preparation method of a solution, comprising the following steps:

[0041] a. adding pyruvic acid compound, osmotic pressure regulator, pH regulator and preservative into water;

[0042] b. heating to 50~60℃, stirring until completely dissolved;

[0043] c. filling into a vaginal applicator.

[0044] A preparation method of a gel, comprising the following steps:

[0045] a. Dissolve the colloid base in part of the water, stir to dissolve after swelling for 12 hours;

[0046] b. Add the pyruvic acid compound, osmotic pressure regulator, pH regulator and preservative into the remaining water, stir to mix and heat to 40-50℃;

[0047] c. Mix the two parts and homogenize at 2500 rpm for 30 minutes;

[0048] d. Fill into a vaginal applicator.

[0049] A method for preparing an emulsion, comprising the following steps:

[0050] a. Add the pyruvic acid compound, osmotic pressure regulator, pH regulator, preservative and emulsifier into water, stir to mix and heat to 60-85℃;

[0051] b. Add the preheated oil phase and homogenize at 3000-3300 rpm for 30 minutes;

[0052] c. Fill into a vaginal applicator.

[0053] Compared with the known prior art, the technical solution provided by the present application has the following beneficial effects:

[0054] Significant improvement in sperm motility:

[0055] The proportion of forward-moving sperm (PR) in the experimental groups (E1-E10) was improved by up to 67.3% (E10 group), the curve speed (VCL) was improved by 51.8% (E5 group), and the survival rate was improved by 38.3% (E10 group), which was much higher than the effect of existing antioxidant or hormone therapy.

[0056] Multi-target synergistic effect:

[0057] The pyruvic acid compound solves the core problem of low sperm motility by simultaneously regulating energy metabolism (providing ATP) and reducing oxidative stress (clearing ROS), avoiding the limitations of single therapy.

[0058] Safety and adaptability:

[0059] The selected pyruvate salts (such as sodium, potassium, magnesium salts) have no cytotoxicity, and the excipients in the dosage form (such as glycerol, hydroxyethyl cellulose) are all pharmaceutical grade, which is highly safe.

[0060] Three dosage forms (solution, gel, emulsion) can be adapted to different clinical scenarios, such as the sustained-release characteristics of the gel which are more suitable for vaginal administration.

[0061] Simple process, easy to promote:

[0062] The preparation process only needs conventional dissolving, homogenizing and filling steps, does not need complex equipment, and is suitable for industrial production.

[0063] The vaginal applicator is designed according to the clinical application requirements, and the patient compliance is improved.

[0064] Clinical value is outstanding:

[0065] The non-hormone and non-surgical treatment options are provided for oligoasthenospermia patients;

[0066] In assisted reproductive technology (such as IVF), the sperm quality can be optimized, and the fertilization success rate is improved. BRIEF DESCRIPTION OF DRAWINGS

[0067] In order to more clearly illustrate the technical solutions of the embodiments of the present application or the prior art, the following will briefly introduce the drawings needed to be used in the embodiment or prior art description. Obviously, the drawings in the following description are only some embodiments of the present application, and for those skilled in the art, other drawings can also be obtained without creative labor on the basis of these drawings.

[0068] Figure 1 The figure is used for comparing the proportions of PR, NP and IM in each group in the present application.

[0069] Figure 2 The figure is used for comparing the VCL, VSL and VAP speed parameters in each group in the present application.

[0070] Figure 3 The figure is used for comparing the sperm survival rate in each group in the present application.

[0071] Figure 4 The figure is used for comparing the survival rate and movement speed correlation in the present application. DETAILED DESCRIPTION

[0072] In order to make the purpose, technical scheme and advantages of the embodiments of the present application more clear, the technical scheme in the embodiments of the present application will be described clearly and completely in the following with reference to the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor are within the scope of protection of the present application.

[0073] The present application will be further described in the following with reference to the embodiments.

[0074] Embodiment 1

[0075] Preparation of solution containing sodium pyruvate

[0076] Prescription: configuration amount: 1000g

[0077]

[0078] Preparation process:

[0079] Take the prescribed amount of glucose, sodium pyruvate, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, polyhexamethylene biguanide, add the rest of the water, and heat to 50-60°C, and fully dissolved. And fill into the vaginal applicator to obtain a solution containing sodium pyruvate, which can be used to improve sperm motility for improving male fertility.

[0080] Example 2

[0081] Preparation of solution containing pyruvic acid, sodium pyruvate

[0082] Prescription: configuration amount: 1000g

[0083]

[0084] Preparation process:

[0085] Take the prescribed amount of sodium pyruvate, pyruvic acid, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, polyhexamethylene biguanide, add the rest of the water, and heat to 50-60°C, and fully dissolved. And fill into the vaginal applicator to obtain a solution containing pyruvic acid, sodium pyruvate, which can be used to improve sperm motility for improving male fertility.

[0086] Example 3

[0087] Preparation of solution containing pyruvic acid, potassium pyruvate

[0088] Prescription: configuration amount: 1000g

[0089]

[0090] Preparation process:

[0091] Take the prescribed amount of potassium pyruvate, pyruvic acid, glucose, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, phenoxyethanol, add the rest of the water, and heat to 50-60°C, and fully dissolved. And fill into the vaginal applicator to obtain a solution containing pyruvic acid, sodium pyruvate, which can be used to improve sperm motility for improving male fertility.

[0092] Example 4

[0093] Preparation of solution containing pyruvic acid, lithium pyruvate

[0094] Prescription: configuration amount: 1000g

[0095]

[0096] Preparation process:

[0097] Take the prescribed amount of lithium pyruvate, pyruvic acid, sorbitol, propylene glycol, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, octanol, add the rest of the water, and heat to 50-60°C, and dissolve thoroughly. And pour into the vaginal applicator to obtain a solution containing pyruvic acid, lithium pyruvate, which can be used to improve sperm motility for improving male fertility.

[0098] Example 5

[0099] Preparation of gel containing pyruvic acid

[0100] Prescription: configuration amount: 1000g

[0101]

[0102] Preparation process:

[0103] 1. Take the prescribed amount of hydroxyethyl cellulose, and use the prescribed amount of 60% water to swell for 12 hours, and dissolve thoroughly with stirring for standby.

[0104] 2. Take the prescribed amount of pyruvic acid, sodium chloride, glucose, disodium hydrogen phosphate, sodium dihydrogen phosphate, polyhexamethylene biguanide, and add the rest of the water, and stir evenly. And heat to 40-50°C, then add the standby liquid of step 1, homogenize in a homogenizing emulsifying tank at 2500 rpm for 30 minutes, and pour into the vaginal applicator to obtain a gel containing pyruvic acid, which can be used to improve sperm motility for improving male fertility.

[0105] Example 6

[0106] Preparation of gel containing pyruvic acid, magnesium pyruvate

[0107] Prescription: configuration amount: 1000g

[0108]

[0109]

[0110] Preparation process:

[0111] 1. Take the prescribed amount of hydroxypropyl methyl cellulose and hydroxyethyl cellulose, and use the prescribed amount of 60% water to swell for 12 hours, and dissolve thoroughly with stirring for standby.

[0112] 2, Take the prescription amount of acetone acid, magnesium acetone acid, glycerol, sorbitol, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, hydroxybenzyl ester, hydroxybenzyl ester, add the rest of the water, and stir evenly. And heated to 40℃-50℃, then add the standby liquid of step 1, homogenized in a homogenizing emulsifying tank at 2500 rpm for 30 minutes, and filled into a vaginal applicator to obtain a gel containing acetone acid and magnesium acetone acid. It can be used to improve sperm motility and improve male fertility.

[0113] Example 7

[0114] Preparation of gel containing acetone acid and calcium acetone acid

[0115] Prescription: configuration amount: 1000g

[0116]

[0117]

[0118] Preparation process:

[0119] 1, Take the prescription amount of gellan gum, and use the prescription amount of 60% water to swell for 12 hours, and fully stir to dissolve for standby.

[0120] 2, Take the prescription amount of acetone acid, calcium acetone acid, glycerol, polyethylene glycol, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, hydroxybenzyl ester, hydroxybenzyl ester, add the rest of the water, and stir evenly. And heated to 40℃-50℃, then add the standby liquid of step 1, homogenized in a homogenizing emulsifying tank at 2500 rpm for 30 minutes, and filled into a vaginal applicator to obtain a gel containing acetone acid and calcium acetone acid. It can be used to improve sperm motility and improve male fertility.

[0121] Example 8

[0122] Preparation of emulsion containing zinc acetone acid

[0123] Prescription: configuration amount: 1000g

[0124]

[0125]

[0126] Preparation process:

[0127] Take the prescription amount of sodium chloride, zinc acetate, mannitol, cetylstearyl alcohol, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, polyhexamethylene biguanide into the prescription amount of water, and stir evenly, and heat to 70~80℃. Then add the preheated (70~80℃) coconut oil to the prescription amount, homogenize in a homogenizing emulsifying tank at 3000 rpm for 30 minutes, and fill into a vaginal applicator to obtain a zinc acetate emulsion, which can be used to improve sperm motility and improve male fertility.

[0128] Example 9

[0129] Preparation of a emulsion containing manganese acetate

[0130] Prescription: configuration amount: 1000g

[0131]

[0132]

[0133] Preparation process:

[0134] Take the prescription amount of sodium chloride, manganese acetate, sodium chloride, sodium lauryl sulfate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, polyhexamethylene biguanide into the prescription amount of water, and stir evenly, and heat to 60~70℃. Then add the preheated (60~70℃) dimethyl silicone oil to the prescription amount, homogenize in a homogenizing emulsifying tank at 3000 rpm for 30 minutes, and fill into a vaginal applicator to obtain a manganese acetate emulsion, which can be used to improve sperm motility and improve male fertility.

[0135] Example 10

[0136] Preparation of a emulsion containing acetate, sodium acetate

[0137] Prescription: configuration amount: 1000g

[0138]

[0139] Preparation process:

[0140] Take the prescription amount of sodium chloride, sodium acetate, acetate, sodium chloride, stearic acid polyethylene glycol ester, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, phenoxy ethanol into the prescription amount of water, and stir evenly, and heat to 75~85℃. Then add the preheated (75~85℃) ethylhexyl palmitate to the prescription amount, homogenize in a homogenizing emulsifying tank at 3300 rpm for 30 minutes, and fill into a vaginal applicator to obtain an acetate, sodium acetate emulsion, which can be used to improve sperm motility and improve male fertility.

[0141] Research on the improvement of sperm motility and speed by acetate compounds

[0142] Refer to WHO Laboratory Manual (6th edition, 2021), ISO 23162:2021 (Standardization of human semen analysis).

[0143] Experimental groups (E1-E10) correspond to the preparation products in Examples 1-10.

[0144] 1. Experimental materials and grouping

[0145] Semen samples: Source: healthy volunteers (abstinence for 2-7 days), semen analysis (in line with WHO standards: PR≥32%, concentration≥15×10 6 / mL).

[0146] Treatment: After liquefaction, mix homogenously, and sub-pack to experimental groups (E1-E10) and control group (C), wherein the control group (C): HTF medium (without additives).

[0147] Experimental method

[0148] 2.1 Sample processing: Dilute the liquefied semen to 10×10 6 / mL with HTF medium.

[0149] Sub-pack 1 mL per group, add corresponding treatment reagents respectively, and incubate in a 37℃, 5% CO2 incubator for 1 hour.

[0150] 2.2 Sperm motility detection

[0151] Equipment: Computer-aided sperm analysis system.

[0152] Parameters: Motility classification: forward movement (PR), non-forward movement (NP), and immotile sperm (IM).

[0153] Movement speed: VCL (curve velocity), VSL (straight-line velocity), and VAP (average path velocity).

[0154] Movement pattern: LIN (linearity) and STR (forwardness).

[0155] 2.3 Data collection

[0156] Each group was repeated 3 times, and the average value was taken.

[0157] Detection time points: 0 hours (baseline), 1 hour (after treatment).

[0158] Experimental results

[0159] 3.1 Data recording and chart

[0160] The sperm motility parameters of each group are shown in Table 1, and the corresponding comparison chart of PR, NP, and IM ratio of each group is shown in Figure 1, VCL, VSL, VAP speed parameter comparison chart see Figure 2 .

[0161] Table 1: Comparison of sperm motility parameters in each group (mean ± standard deviation)

[0162]

[0163]

[0164] *p<0.05 (significantly different from control group C),

[0165] **p<0.01 (extremely significantly different from control group C)

[0166] 4. Conclusion: The experimental results are summarized

[0167] 4.1 Improved motility: The PR of all experimental groups (E1-E10) was significantly higher than that of the control group (p<0.05), with E10 showing the most significant improvement (+67.3%). E5 and E8 showed the best improvement in VCL (+51.8% and +49.6%, respectively).

[0168] 4.2 Speed and trajectory optimization: E1 and E3 significantly improved LIN and STR (p<0.01), indicating that the movement direction is more linear.

[0169] 4.3 Synergistic effect: E10 showed that multi-target intervention has more advantages.

[0170] Therefore, it can be proved that the preparation containing pyruvate compounds has a significant effect on improving sperm motility and speed.

[0171] Study on the improvement of sperm survival rate by pyruvate compounds

[0172] Based on the WHO standard (6th edition) and the "Human Sperm Examination and Processing Laboratory Manual".

[0173] Experimental groups (E1-E10) correspond to the preparation products in Examples 1-10.

[0174] Experimental materials and grouping

[0175] 1.1 Sample source: healthy volunteers (n=15, abstinence for 2-7 days), semen parameters meet WHO standards (PR≥32%, concentration≥15×10 6 / mL)

[0176] 1.2 Grouping: Control group (C): HTF medium (no addition)

[0177] Experimental groups (E1-E10): HTF medium + different survival rate enhancers (concentration optimized by pre-experiment)

[0178] 1.3 Detection index: sperm survival rate (trypan blue staining method), motility parameters (CASA).

[0179] Experimental methods

[0180] 2.1 Sample processing

[0181] - After semen liquefaction, dilute to 20 x 10 6 / mL

[0182] - Sub-packaged into E1-E10 groups and control group, 1 mL per group

[0183] - Incubate in a 37°C, 5% CO2 incubator for 2 hours

[0184] 2.2 Survival rate detection

[0185] - Trypan blue staining: mix sperm suspension with 0.4% trypan blue (1:1), stand for 3 minutes

[0186] - Count 200 sperm under a hemocytometer, uncolored sperm are live sperm (survival rate = number of live sperm / total number x 100%)

[0187] 3. Motility detection:

[0188] - Computer-assisted sperm analysis (CASA): detect VCL parameters

[0189] Experimental results

[0190] Sperm survival rate and VCL parameters of each group are shown in Table 2, comparison of sperm survival rate of each group is shown in Figure 3 , and the correlation between sperm survival rate and motility of each group is shown in Figure 4 .

[0191] Table 2: Sperm survival rate and VCL of each group (mean ± SD)

[0192]

[0193]

[0194] ** p <0.01 (extremely significant difference compared with control group C)

[0195] 4. Conclusion:

[0196] Summary of experimental results

[0197] 4.1 Survival rate improvement: The survival rate of all experimental groups was significantly higher than that of the control group (p<0.01), among which the E10 group had the largest improvement (+38.3%). The survival rates of the E5, E7 and E10 groups were all >75%, close to the clinical high-quality sperm standard (>75%).

[0198] 4.2 Motion ability improvement:

[0199] VCL was positively correlated with the survival rate (R 2 =0.92), indicating that the improvement of the survival rate was accompanied by the enhancement of the motion ability.

[0200] The VSL of the E10 group was optimal, indicating that the motion direction tended to be more linear.

[0201] Therefore, it can be proved that the pyruvate compound-containing preparation has a significant ability to improve the survival rate of sperm.

[0202] The above examples are only used to illustrate the technical solutions of the present application, but not to limit it; although the present application has been described in detail with reference to the foregoing examples, those skilled in the art should understand that the technical solutions recorded in the foregoing examples can still be modified, or some technical features can be replaced by equivalents; and these modifications or replacements will not make the essence of the corresponding technical solutions deviate from the protection scope of the technical solutions of the embodiments of the present application.

Claims

1. Use of a pyruvic acid compound for increasing the motility of spermatozoa, characterized in that, The pyruvic acid compound is selected from pyruvic acid, pyruvic acid salt or mixture thereof, the pyruvic acid salt is one or more of lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate or manganese pyruvate.

2. Use according to claim 1, characterized in that, The application is achieved by preparing pyruvic acid compound into a medicine or health product, which is a solution, comprising the following components by mass percentage: Pyruvic acid compound: 0.1%~1.5%; Osmotic pressure regulator: 0.5%~2%; pH regulator: 0.1%~2.5%; Preservative: 0.01%~0.5%; The balance is water.

3. Use according to claim 1, characterized in that, The medicine or health product is a gel, comprising the following components by mass percentage: Pyruvic acid compound: 0.1%~1.5%; Colloid base: 0.2%~1%; Osmotic pressure regulator: 0.5%~2%; pH regulator: 0.1%~2.5%; Preservative: 0.01%~0.5%; The balance is water.

4. Use according to claim 1, characterized in that, The medicine or health product is an emulsion, comprising the following components by mass percentage: Pyruvic acid compound: 0.1%~1.5%; Oil phase: 15%~35%; Osmotic pressure regulator: 0.5%~2%; pH regulator: 0.1%~2.5%; Preservative: 0.01%~0.5%; Emulsifier: 0.1%~0.5%; The balance is water.

5. Use according to claim 2, characterized in that, The osmotic pressure regulator is selected from one or more of glycerol, glucose, sodium chloride, mannitol, sorbitol, polyethylene glycol or propylene glycol; the pH regulator is selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate or potassium dihydrogen phosphate; the preservative is selected from one or more of polyhexamethylene biguanide, hydroxybenzoic acid methyl ester, hydroxybenzoic acid propyl ester, phenoxy ethanol or octanol.

6. Use according to claim 3, characterized in that, The colloid base is selected from one or more of hydroxypropyl methyl cellulose, hydroxyethyl cellulose, sodium alginate or gellan gum.

7. Use according to claim 4, characterized in that, The oil phase is selected from one or more of jojoba oil, grape seed oil, sweet almond oil, olive oil, sunflower seed oil, coconut oil, dimethyl silicone oil, isopropyl myristate, ethylhexyl palmitate, caprylic / capric acid triglyceride, white mineral oil or vaseline; the emulsifier is selected from one or more of Tween 20, Tween 80, polyethylene glycol stearate, cetyl stearyl alcohol polyether, sodium dodecyl sulfate, lecithin, cetyl stearyl alcohol, sucrose ester or glycerol stearate.

8. A method for preparing a solution for use in the application of claim 2, characterized by, The steps include: a. Add pyruvic acid compound, osmotic pressure regulator, pH regulator and preservative to water; b. Heat to 50~60℃, stir until completely dissolved; c. Fill into a vaginal applicator.

9. A method of preparing a gel for use in the application of claim 3, characterized by, The steps include: a. Dissolve the colloid base in part of the water, stir to dissolve after swelling for 12 hours; b. Add pyruvic acid compound, osmotic pressure regulator, pH regulator and preservative to the remaining water, stir evenly and heat to 40~50℃; c. Mix the two parts, homogenize at 2500 rpm for 30 minutes; d. Fill into a vaginal applicator.

10. A method for the preparation of an emulsion for use according to claim 4, characterized in that, The steps include: a. Add pyruvic acid compound, osmotic pressure regulator, pH regulator, preservative and emulsifier into water, stir uniformly and heat to 60-85°C; b. Add preheated oil phase, homogenize at 3000-3300 rpm for 30 minutes; c. Fill into vaginal applicator.

Images